evenfolio

Chemicals · NSE: PIDILITIND

Pidilite Industries

Price as of 12 Nov 2026
1,579.70+0.34%

Q2 FY27 earnings call · Guided by management

Call held 29 Oct 2026 · Read the filing on NSEFiling

20–24​%EBITDA margin · H2 FY27Vats · p. 6
3–5​%Price increaseVats · Q&A · p. 9
6–7​pilotsPilots completed · Exterior rendersVats · Q&A · p. 15
M.Cap
₹1,60,794Cr₹1.61L Cr
P/E
59.9×
1Y return
+6.59%
From 52W high
−7.5%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue4,2983,554+20.9%4,552-5.6%
EBITDA877851+3.1%1,194-26.5%
EBITDA margin20.4%23.9%-351 bps26.2%-581 bps
One-off items———14—
PBTProfit before tax829788+5.3%1,190-30.3%
Net profit615579+6.1%872-29.6%
EPS (₹)6.035.68+6.2%8.55-29.5%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

EBITDA margin · H2 FY2720-24%H2 EBITDA margin expected in 20% to 24% corridor, ideally at the higher end

UVG should stay double digit if real GDP growth is 6.5-7%

Sudhanshu Vats · Managing Director · Q&A · p. 11
“If the country's growth is in the 6.5, 7 range in real terms, our UVG growth should remain double digit and we would like to keep inching it up that because a lot of these things we do, we create a lot of demand ourselves.”

Double-digit UVG is the short-term target

Sudhanshu Vats · Managing Director · Q&A · p. 16
“So, for a short-term perspective, I think this is a number we would like to deliver, which is a double digit.”

Desire to take UVG from double digit to early teens over time

Sudhanshu Vats · Managing Director · Q&A · p. 16
“And so, therefore, we will continue and we want to take this from classic double digit to early teens. I think that's the desire over a period of time.”

In short

  1. 01Management expects H2 FY27 EBITDA margin within its 20% to 24% corridor, ideally at the higher end.
  2. 02Q2 stand-alone revenue grew 21.7% with underlying volume growth of 10.7%; EBITDA margin was 20.4%.
  3. 03Q2 VAM consumption rate was $1,630, nearly double last year; gross margin fell 720 bps.
  4. 04Price rise taken on Fevicol and Dr. Fixit on October 1; a further 3% to 5% rise is planned in high-inflation areas.
  5. 05Underlying volume growth expected to stay double digit, with a desire to reach early teens over time.
  6. 06El Nino, elevated crude and West Asia conflict impact are not fully baked in; demand reported as robust so far.
  7. 07Management sees no cost advantage in setting up its own VAM plant.

Capex

Company has evaluated own VAM plant multiple times

Sudhanshu Vats · Managing Director · Q&A · p. 18
“I think, see, we have evaluated VAM ourselves or with one of our large international partners multiple times.”

A VAM plant below global scale may not help on pricing, says management

Sudhanshu Vats · Managing Director · Q&A · p. 18
“So therefore, having a suboptimal size may not help you from pricing in the long term.”

Own VAM plant does not give a cost advantage, says management

Sudhanshu Vats · Managing Director · Q&A · p. 19
“point of view of cost advantage, I think it doesn't work for us.”

Capacity

Exterior renders: Considering more render plants beyond current Rajasthan facility

Kavinder Singh · Joint Managing Director · Q&A · p. 20
“And as the momentum is building up, we are already trying to see whether we need to put up more plants of this particular render production if it can be done beyond the current facility that we have in Rajasthan.”

Segments

Consumer and Bazaar: Q2 Consumer and Bazaar UVG was 11.1%; B2B UVG was 9.2%

Sandeep Batra · Executive Director and Chief Financial Officer · p. 3
“Consumer and Bazaar growth in the quarter was quite broad-based with Consumer and Bazaar UVG was 11.1% and B2B UVG was 9.2%.”

International subsidiaries: International subsidiaries grew 21.8% in the quarter

Sandeep Batra · Executive Director and Chief Financial Officer · p. 3
“Our subsidiary performance was good for the quarter with international subsidiaries growing by 21.8%.”

International subsidiaries: International subsidiaries EBITDA grew 53%

Sandeep Batra · Executive Director and Chief Financial Officer · p. 4
“EBITDA in the international subsidiaries also improved with a growth of 53% versus the top line growth of 21.8%.”

Domestic subsidiaries: Domestic subsidiaries revenue grew 22.2%; Consumer and Bazaar and B2B both grew 22%

Sandeep Batra · Executive Director and Chief Financial Officer · p. 4
“Domestic subsidiaries too delivered a strong quarter with a revenue growth of 22.2%, again, led by the Consumer and Bazaar businesses, which grew by 22% and B2B businesses grew by also 22%.”

Domestic subsidiaries: Domestic subsidiaries other than Nina all grew above 20%

Sandeep Batra · Executive Director and Chief Financial Officer · Q&A · p. 9
“As I mentioned in my opening remarks, the only business which has seen some headwind, it happens in the monsoon period has been Nina. Others have all grown north of 20%.”

Demand

No fundamental shift in competitive intensity seen

Sudhanshu Vats · Managing Director · Q&A · p. 7
“I wouldn't say that there is any fundamental shift in competitive intensity.”

Demand reasonably robust; third quarter entered well

Sudhanshu Vats · Managing Director · Q&A · p. 11
“It is hard to bake them in fully but as of now, we can assure you that we are seeing reasonably robust demand. You have seen our first quarter number. We have entered third quarter quite well.”

Urban growth slightly ahead of rural in Q2, first time in a long time

Sudhanshu Vats · Managing Director · Q&A · p. 13
“Arguably in Q2 for the very first time after a long time, urban is slightly ahead of rural.”

Exterior renders: Renders can be 15% to 20% of conventional exterior walls in Southern Europe

Sudhanshu Vats · Managing Director · Q&A · p. 15
“So, this in Europe, in Southern Europe, where this has been around for some time, this can be 15% to 20% of all exterior walls is done in a conventional sense, not the glass and steel towers, which come up now, the conventional ones.”

No improvement in macro assumed for rest of the year

Sudhanshu Vats · Managing Director · Q&A · p. 17
“So therefore, we are not building any improvement in macro for the rest of the year.”

Margins and costs

Q2 VAM consumption rate was $1,630, nearly double last year, vs $1,370 in Q1

Sandeep Batra · Executive Director and Chief Financial Officer · p. 3
“We always refer to what has been the VAM consumption rate, which in the second quarter was $1,630, nearly double of what it was in the same period last year and versus $1,370 in the first quarter.”

Gross margin fell 720 bps; EBITDA margin fell 430 bps to 20.4%, lower end of range

Sandeep Batra · Executive Director and Chief Financial Officer · p. 3
“However, because of the robust top line growth, we got operating leverage, and against the 720 basis points decline in gross margin, our EBITDA was lower by 430 basis points and came in at the lower end of our range, at 20.4%.”

H1 EBITDA margin at 23.5%, towards upper end of range

Sandeep Batra · Executive Director and Chief Financial Officer · p. 4
“was 8.3%, and our H1 EBITDA again came in strong, very much towards the upper end of the range at 23.5%.”

VAM shot up to almost $2,000 after West Asia conflict began

Sudhanshu Vats · Managing Director · p. 5
“As soon as West Asia conflict happened, VAM actually shot up to almost $2,000, if I am not mistaken, just $2,000 really shot up.”

Q1 FY27 in-quarter EBITDA margin was 26.3%

Sudhanshu Vats · Managing Director · p. 5
“We delivered a very robust in-quarter EBITDA margin of 26.3%, surprising most people actually.”

Acquisitions and new business

Fevicol: Fevicol Multi Lock and X-Per going national in November after pilots

Sudhanshu Vats · Managing Director · p. 8
“on Fevicol, we have piloted products called Multi Lock and X-Per. They are going national in November.”

Dr. Fixit: Dr. Fixit Wonderproof product is doing well

Sudhanshu Vats · Managing Director · p. 8
“In Dr. Fixit, we have a product called Wonderproof which is actually doing really well as we are doing distinct.”

M-Seal: M-Seal Advance being piloted

Sudhanshu Vats · Managing Director · p. 8
“If you look at M-Seal as a brand, we are just piloting a product called M-Seal Advance, which brings multiple features, one amongst them is to be able to wash your hand very easily and so on and so forth.”

Araldite: Araldite White X and Wud X are new products for the premium segment

Sudhanshu Vats · Managing Director · Q&A · p. 8
“And similarly, Araldite White X and Araldite Wud X are for the premium segment.”

Consumer and Bazaar: New Stainoff getting good response on quick commerce

Sudhanshu Vats · Managing Director · p. 8
“Our new Stainoff, which has just been done, is getting a very good response on quick commerce and so on and so forth.”

One-offs

Q1 benefited from low-cost inventory carried from Q4 FY26

Sudhanshu Vats · Managing Director · p. 5
“And we also got the advantage in quarter 1, as Sandeep also pointed out, of low-cost inventory coming in from previous quarter, Q4 of FY26.”

Risks

Nina: Nina saw revenue headwinds due to lack of waterproofing workfront

Sandeep Batra · Executive Director and Chief Financial Officer · p. 4
“The only business that saw some revenue headwinds was Nina, which had challenges because they did not have adequate workfront available for doing waterproofing.”

Crude noted as elevated at about $115

Sudhanshu Vats · Managing Director · p. 4
“So, therefore, and you have seen crude is elevated at about $115.”

Impact of latest pricing, El Nino, crude and West Asia not fully baked in

Sudhanshu Vats · Managing Director · Q&A · p. 11
“The latest round of pricing, which we are doing, El Nino, which is also going to have some effect, and elevated crude, if it remains and the last unknown is if West Asia conflict flares up even further - impact of those items are not fully baked in.”

Exports: Exports into or through West Asia still underperforming

Sudhanshu Vats · Managing Director · Q&A · p. 17
“Our exports to be honest with you, our exports out of India into West Asia or going shipped through West Asia, that area are still underperforming because there are challenges in that space.”

Competitor VAM plant seen as no specific advantage or disadvantage

Sudhanshu Vats · Managing Director · Q&A · p. 19
“We see no specific advantage. And to that extent, no specific disadvantage to us with this plant coming up.”

Other

Q2 stand-alone revenue grew 21.7% with underlying volume growth of 10.7%

Sandeep Batra · Executive Director and Chief Financial Officer · p. 3
“In the current quarter, our stand-alone revenue was under INR4,000 crores with a growth of 21.7% in nominal terms and underpinned by underlying volume growth of 10.7%, which was broad-based.”

H1 stand-alone revenue grew 22% with UVG of 11%

Sandeep Batra · Executive Director and Chief Financial Officer · p. 4
“And therefore, in H1, if I were to look at our stand-alone revenues grew by 22%, UVG was 11%.”

New brand campaigns for Roff and Dr. Fixit to be seen more in Q3

Sudhanshu Vats · Managing Director · p. 10
“So you will see Roff and Dr. Fixit a lot more in Q3 as well.”

AI first used for effectiveness; manpower reduction a later discussion

Sudhanshu Vats · Managing Director · Q&A · p. 12
“Efficiency that we will drive from it, productivity and reduction in manpower will be a subsequent discussion.”

H1 UVG at 11% vs 10.1% last year

Sandeep Batra · Executive Director and Chief Financial Officer · Q&A · p. 16
“And if you see even first half, Keyur, last year was 10.1%. And this year, first half is 11%.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools